Motexafin gadolinium (MGd) combined with whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase III trials Conference

Shapiro, WR, Mehta, MP, Langer, C et al. (2007). Motexafin gadolinium (MGd) combined with whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase III trials . JOURNAL OF CLINICAL ONCOLOGY, 25(18),

Industry Collaboration International Collaboration

cited authors

  • Shapiro, WR; Mehta, MP; Langer, C; Bezjak, A; Timmerman, R; Brachman, D; Suh, J; Smith, JA; Phan, S; Renschler, MF

sustainable development goals

authors

publication date

  • June 20, 2007

webpage

published in

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

publisher

  • AMER SOC CLINICAL ONCOLOGY

volume

  • 25

issue

  • 18